Page 1

Ortho Clinical Diagnostics Ortho Clinical Diagnostics Reports Third Quarter 2021 Results November 3 , 2021 Highlights Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics • Third quarter revenue increased 15.8 % to $ 522.5 million , or 14.3 % in constant currency • Core revenue grew 14.8 % to $ 508.9 million for the quarter , or 13.2 % in constant currency ● Strength across all major geographic regions , including double - digit growth in both developed and emerging markets • Operating income increased 161.0 % to $ 54.0 million from $ 20.7 million last year • GAAP Net Income was $ 14.7 million , or $ 0.06 per diluted share , while Adjusted Net Income was $ 50.9 million , or $ 0.21 per diluted share in the third quarter of 2021 • Third quarter Adjusted EBITDA rose 16.8 % year - over - year to $ 139.6 million and Adjusted Free Cash Flow increased $ 26.3 million year - over year to $ 56.3 million RARITAN , N.J. , Nov. 03 , 2021 ( GLOBE NEWSWIRE ) -- Ortho Clinical Diagnostics Holdings plc ( Nasdaq : OCDX ) ( the " Company " ) , one of the world's largest pure - play in - vitro diagnostics ( IVD ) companies , today announced financial results for the third quarter ended October 3 , 2021 . Third Quarter 2021 Financial Highlights " Our team delivered another excellent quarter , with profitable growth across all major geographic regions . Both our Clinical Laboratories and Transfusion Medicine businesses grew double - digits , supported by our strong recurring revenue base , " said Chris Smith , Chairman and Chief Executive Officer of Ortho Clinical Diagnostics . " Building on the strong momentum from the last couple of years , our commercial excellence program continues to improve our execution and drive mid - teens growth of our integrated system installed base - key to our lifetime customer value and accelerated recurring revenue pull - through . This strong positioning provides us with significant opportunity to carry our strength forward into the fourth quarter and into 2022. " $ in millions , other than per share amounts Net Revenue Core Revenue Gross Profit Margin Income from Operations EPS ( GAAP ) Quarter Ended October 3 , 2021 $ 522.5 $ 508.9 51.7 % $ 54.0 $ 0.06 $ 0.21 $ 56.3 $ 139.6 September 27 , 2020 $ 451.1 $ 443.3 48.1 % $ 20.7 ( $ 0.20 ) $ 0.14 $ 30.0 $ 119.5 Change As Reported 15.8 % 14.8 % 359 bps 161.0 % $ 0.26 $ 0.07 $ 26.3 16.8 % Constant Currency 14.3 % 13.2 % Adjusted Diluted EPS Adjusted Free Cash Flow Adjusted EBITDA Changes presented in the table above have been calculated using actual , non - rounded amounts and may not recalculate . • Core revenue , which excludes contract manufacturing and collaboration revenue , increased to $ 508.9 million in the third quarter of 2021 , compared with $ 443.3 million in the similar period last year , or a 13.2 % increase in constant currency terms • Adjusted Net income for the third quarter was $ 50.9 million , or $ 0.21 per share , compared with $ 21.0 million , or $ 0.14